Targeting the latent virus in certain aggressive lymphomas
Targeting Latency Switch in EBV+ Lymphomas
This study is looking at a type of aggressive lymphoma linked to the Epstein-Barr virus and is testing a drug called decitabine to help make these tumors easier for the immune system to fight, with the hope of improving treatment for patients facing this tough cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10883621 on NIH RePORTER |
What this research studies
This research focuses on aggressive lymphomas associated with the Epstein-Barr virus (EBV), which can evade the immune system by remaining in a latent state. The team aims to reprogram these tumors from a less immunogenic state to a more immunogenic one, making them more susceptible to immune attack. They will use a drug called decitabine, which has shown promise in laboratory settings to enhance the immune response against these cancers. By converting latency I tumors to a more aggressive form, the goal is to improve treatment outcomes for patients with these challenging malignancies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with EBV-associated lymphomas, particularly those with Burkitt lymphoma or HIV-associated diffuse large B-cell lymphoma.
Not a fit: Patients with lymphomas not associated with EBV or those who do not have aggressive forms of lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with EBV-associated lymphomas, potentially improving survival rates.
How similar studies have performed: Previous research has shown that similar approaches using epigenetic reprogramming have been successful in enhancing immune responses in other cancer types.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Roth, Lisa Giulino — Weill Medical Coll of Cornell Univ
- Study coordinator: Roth, Lisa Giulino
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.